ArticleBioorganic & medicinal chemistry2026
Triazole-based STING inhibitors.
Article in Bioorganic & medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biological Evaluation, Molecular Docking, and in Ovo Hatchability Assessment of Selected Mannich-Type 1,2,4-Triazol-5-one Derivatives.International journal of molecular sciences · 2026Article
- The Development of UM-232, a Covalent STING Antagonist.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aberrant activation of the DNA sensing cGAS-STING pathway has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus (SLE), and autoinflammatory disorders such as Aicardi-Goutières syndrome (AGS) and STING-associated vasculopathy with onset in infancy (SAVI). Consequently, considerable efforts have been directed toward the development of STING inhibitors. We previously reported that BB-Cl-amidine and LB244 inhibit STING-dependent signalling with nanomolar potency both in vitro and in vivo. The nitrofuran warhead on LB244 provided superior potency and proteome-wide selectivity. Moreover, LB244 mirrored the efficacy of BB-Cl-amidinein vivo. Herein, we describe the development of a series of triazole-based analogues designed to inhibit STING signalling. These efforts led to the development of ASF24, a highly potent inhibitor of STING signalling (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.